Moderna Stock Vs Novavax

Moderna has the ability to produce around 20 million does of mrna 1273 by the end of 2020.

Moderna stock vs novavax. Nvax is yet to start its central study in the us. As novavax has been conducting its third and final phase of the clinical trial of the covid 19 vaccine called nvx cov2373 in the united kingdom nasdaq. Moderna is well capitalized thanks to a secondary stock offering in may. Hopes of a covid.

Novavax stock has soared over 20x year to date while moderna is up 3x driven largely by the covid 19 vaccine efforts. Nvax moderna a clinical stage biotech company is carrying out phase 3 trials of its covid 19 vaccine completing enrollment of 30 000 participants. Novavax has more capacity to produce and sell vaccines than moderna. Novavax these biotechs are racing to develop a vaccine for the novel coronavirus.

Moderna has undoubtedly been enjoying a great start and power over novavax in the coronavirus vaccine race to the finish line. If such a position comes up moderna stock would fall hugely. Here are highlights from wednesday s analyst blog. The case for novavax.

Moderna definitely enjoys something of a head start over novavax in this race. The biotech raised gross proceeds of 1 34 billion to fund its development programs. As of now novavax appears to has a greater edge in the vaccine production of the novel coronavirus than moderna. Stocks recently featured in the blog include.

While novavax has a phase 3 clinical study for its experimental covid 19 vaccine nvx cov2373 underway in the u k it. The stock has soared 2 000 year to date. Nvax stand out as two of the leaders in this race to develop a covid 19 vaccine. Which stock is the better choice.

Pipeline beyond covid 19 vaccine.